Infant Bacterial Therapeutics AB Class B IBT_B
OMXSTO · Sweden · Health Technology
SEK 69.90-0.50 (-0.71%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics Market by Type of Product, Route of Administration, Target Indication, Therapeutic Area, End User and Geographical Regions - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global microbiome therapeutics market is projected to increase from USD 0.6 billion in 2026 to USD 4.6 billion by 2035, registering a compound annual growth rate of 25.4% during the forecast period. Market expansion
UPPSALA, SE / ACCESS Newswire / July 7, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica International AB today announced the appointment of Maria Ekdahl as Chief Financial Officer (CFO). Ekdahl brings more than 20 years ...
UPPSALA, SE / ACCESS Newswire / July 7, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica International AB today announced the appointment of Maria Ekdahl as Chief Financial Officer (CFO). Ekdahl brings more than 20 years ...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.